Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
Grace Lai-Hung Wong
Clin Mol Hepatol. 2018;24(2):108-113.   Published online 2018 Jan 22     DOI:
Citations to this article as recorded by Crossref logo
Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
Hye Won Lee, Seung Up Kim, Baatarkhuu Oidov, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
Scientific Reports.2019;[Epub]     CrossRef
Updated Treatment of Chronic Hepatitis B
Eileen L. Yoon, Hyung Joon Yim
The Korean Journal of Medicine.2019; 94(3): 252.     CrossRef
Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant
Pil Soo Sung, Dong Jun Park, Jung-Hee Kim, Ji Won Han, Eun Byul Lee, Gil Won Lee, Hee Chul Nam, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Eui-Cheol Shin, Su-Hyung Park, Seung Kew Yoon
Frontiers in Immunology.2019;[Epub]     CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?
Nae-Yun Heo
The Korean Journal of Gastroenterology.2019; 74(1): 66.     CrossRef
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
Won Hyeok Choe, Ki Jeong Kim, So Young Lee, Yu Min Choi, So Young Kwon, Jeong Han Kim, Bum Joon Kim
World Journal of Gastroenterology.2019; 25(33): 4985.     CrossRef